Geode Capital Management LLC Purchases 174,940 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)

Geode Capital Management LLC boosted its position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Free Report) by 73.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 413,677 shares of the company's stock after buying an additional 174,940 shares during the quarter. Geode Capital Management LLC owned approximately 1.39% of Telomir Pharmaceuticals worth $1,705,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Rhumbline Advisers grew its position in shares of Telomir Pharmaceuticals by 105.9% in the fourth quarter. Rhumbline Advisers now owns 8,600 shares of the company's stock valued at $35,000 after purchasing an additional 4,424 shares in the last quarter. Corebridge Financial Inc. boosted its position in shares of Telomir Pharmaceuticals by 273.8% during the 4th quarter. Corebridge Financial Inc. now owns 9,613 shares of the company's stock valued at $40,000 after acquiring an additional 7,041 shares during the last quarter. Barclays PLC grew its holdings in shares of Telomir Pharmaceuticals by 325.1% during the third quarter. Barclays PLC now owns 7,018 shares of the company's stock worth $45,000 after purchasing an additional 5,367 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Telomir Pharmaceuticals in the fourth quarter worth approximately $62,000. Finally, JPMorgan Chase & Co. raised its stake in Telomir Pharmaceuticals by 1,096.4% in the fourth quarter. JPMorgan Chase & Co. now owns 41,444 shares of the company's stock valued at $171,000 after purchasing an additional 37,980 shares in the last quarter.

Telomir Pharmaceuticals Trading Up 0.4 %

Shares of TELO stock traded up $0.01 during mid-day trading on Monday, reaching $2.60. The stock had a trading volume of 18,435 shares, compared to its average volume of 131,084. The firm has a market capitalization of $77.38 million, a PE ratio of -4.48 and a beta of 0.17. Telomir Pharmaceuticals, Inc. has a 52-week low of $2.35 and a 52-week high of $8.40. The stock's 50-day moving average price is $3.41 and its two-hundred day moving average price is $4.14.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.05). On average, equities research analysts forecast that Telomir Pharmaceuticals, Inc. will post -0.4 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. RODMAN&RENSHAW raised shares of Telomir Pharmaceuticals to a "strong-buy" rating in a report on Thursday, February 20th. Rodman & Renshaw initiated coverage on Telomir Pharmaceuticals in a research report on Friday, February 21st. They issued a "buy" rating and a $15.00 price objective for the company.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.